医学
肾脏替代疗法
重症监护医学
美罗培南
人口
加药
肾脏疾病
内科学
抗生素
抗生素耐药性
生物
微生物学
环境卫生
作者
William James Earle,Ramon Bonegio,Donald B. Smith,Westyn Branch‐Elliman
出处
期刊:Case Reports
[BMJ]
日期:2021-08-01
卷期号:14 (8): e243609-e243609
被引量:2
标识
DOI:10.1136/bcr-2021-243609
摘要
A 75-year-old man presented with shortness of breath and somnolence and was found to have urosepsis. Blood and urine cultures subsequently grew multidrug-resistant (MDR) Klebsiella pneumoniae (Kp) with the New Delhi metallo-β-lactamase gene. The patient was treated successfully with plazomicin and meropenem/vaborbactam combination therapy. The course was complicated by acute kidney injury temporarily requiring haemodialysis, gastrointestinal bleed requiring multiple transfusions and hospital readmission with blood cultures again positive with MDR Kp. Plazomicin drug levels were persistently high during treatment, suggesting that therapeutic drug monitoring may be needed to safely use this drug in patients with severe renal dysfunction. This case marks the first use of plazomicin for bacteraemia in the literature outside of a clinical trial and demonstrates its safe and effective use in a patient with advanced renal disease, and provides important insights about dosing and therapeutic drug monitoring considerations in this patient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI